Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Sutro Biopharma (NASDAQ:STRO) with a $10 price target.
May 15, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson has reiterated an Outperform rating for Sutro Biopharma, maintaining a $10 price target. This suggests confidence in the company's future performance.
The reaffirmation of an Outperform rating and a $10 price target by a reputable analyst can boost investor confidence in Sutro Biopharma, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100